Manufacturing Chemist recently published ‘Optimising dry powder inhaler programmes through formulation’, an analysis on the use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action
In the article, Nikki Willis – Vice President of Pharmaceutical Development, shared her expertise on the challenges in dry powder formulations, compatibility with device materials, integrated development strategies and more.
Dry powder formulation can also increase patient compliance compared with administration via a nebuliser or pressurised metered dose inhaler (pMDI). Compared with nebulised delivery, which, until recently, has been largely limited to use in hospital settings, dry powder inhalers (DPIs) are small, portable and generally deliver the treatment in one or two breaths.
You can read the full article ‘Optimising dry powder inhaler programmes through formulation’, here.